and Association with Paclitaxel Pharmacokinetics. Clin Pharmacol Ther 81, 76-82

Transcription

1 Original Papers Rezvani K, Yong AS,Tawab A, Jafarpour B, Enaife R, Mielke S, Savani BN, Keywanfar K, Li Y, Kurlander R, Barett AJ (2009). Ex vivo charecterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia an acute an chronic myeloid leukemia. Blood 113, Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ, Barrett AJ (2008): A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ (2008): Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, Mielke S*, Rezvani K*, Savani BN, Nunes R, yong ASM, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ (2007):Reconstitution of foxp3+ regulatory T cells (T regs ) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD). Blood 100, [*authors contributed equally] Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong ASM, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ (2007): Natural killer cell recovery strongly influences major transplant outcomes following T cell depleted HLA identical stem cell transplantation. Leukemia 21, Savani BN, Mielke S, Rezvani K, Montero A, Yong ASM, Wisch L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ (2007): Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T-cell depleted allogeneic stem cell transplantation, Biol Blood Marrow Transpl 13, Solomou EE, Rezvani K*, Mielke S*, Malide D*, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS (2007): Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia [Brief report], Blood 110, [*authors contributed equally] Rezvani K, Yong ASM, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price D, Douek D, Barrett AJ (2007): Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 110, Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A (2007): Variants in the SLCO1B3 gene: Interethnic Distribution

2 and Association with Paclitaxel Pharmacokinetics. Clin Pharmacol Ther 81, Yong ASM, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ (2007): High PR3 or ELA2 expression by CD34+ cells in advanced phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide driven graft-versus-leukemia effects. Blood 110, Rezvani K*, Mielke S*, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ (2006): Reconstitution of Foxp3-positive regulatory T-cells (TREGS) following HLA-matched T-depleted allogeneic stem cell transplantation (SCT): relationship of donor and patient TREGS with GVHD, Blood 108, [*authors contributed equally] Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Childs R, Leitman SF, CS Carter, EJ Read, Barrett AJ (2006): Factors associated with early molecular remission following T cell depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107, Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ (2006): Chronic GVHD and pre-transplant abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long term survivors after stem cell transplantation. Biol Blood Marrow Transplant 12, Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ (2006): T-cell depleted peripheral blood stem cell allotransplantation for patients with hematological malignancies: Effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 12, Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S (2006): Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42, Mielke S, Sparreboom A, Steinberg S, Gelderblom H, Unger C, Behringer D, Mross K (2005): Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11, Mielke S, Sparreboom A, Behringer D, Mross K (2005): Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 25, Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman S, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett JA (2005): Selective depletion of alloreactive donor lymphocytes a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 105,

3 Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005): Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. Clin Cancer Res 11, Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, AJ Barrett (2005): T-cell responses directed against multiple HLA A*0201-restricted epitopes derived from WT1 in patients with leukemia and healthy donors: identification, quantification and characterization, Clin Cancer Res, 11, Jackisch C, Grothey A, Schlotter CM, Mielke S, Waßmann KI, Behringer D, Mross K, Rody A (2004): Practical aspects in the treatment of metastatic breast cancer with administration of paclitaxel weekly. [Praktische Aspekte der Therapie des metastasierten Mammakarzinoms mit Paclitaxel-weekly.] Geburtsh Frauenheilk 64, Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, Lange W, Behringer D (2003): Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14, Mross K, Häring B, Holländer N, Mielke S, Behringer D, Unger C (2002): Comparison of the 1-hour and 3-hours paclitaxel infusion pharmacokinetics: Results from a randomized trail. Onkologie 25, Gelderblom H, Mross K, Tije AJ, Behringer D, Mielke S, Zomeren DM, Verweij J, Sparreboom A (2002): Comparative pharmacokinetics of unboundpaclitaxel during 1- and 3- hour infusions. J Clin Oncol 20, Jakob M, Mielke S, Keller H, Metzger U (1999): Results of therapy after primary conservative management of distal radius fractures in patients over 65 years of age. [Therapieergebnisse nach primär konservativer Versorgung distaler Radiusfrakturen bei Patienten im Alter von über 65 Jahren.] Handchir Mikrochir Plast Chir 31, Mielke S, Meden H, Kuhn W (1998): Expression of the c-erbb-2 encoded oncoprotein p185 HER-2/neu in pregnancy as a model for oncogene-induced carcinogenesis. Med Hypotheses 50, Mielke S, Meden H, Marx D, Wuttke W, Kuhn W (1997): In vivo effects of estrogens on c- erbb-2 oncoprotein levels in chorionic villous tissue and maternal serum. Gynecol Endocrinol 11, Mielke S, Meden H, Raab T, Wuttke W, Kuhn W (1997): Effects of interfering and influencing factors on the analyses of p105 (c-erbb-2, HER-2) oncoprotein fragment in serum. Anticancer Res 17,

4 Meden H, Mielke S, Schauer A, Kuhn W (1997): Serum levels of the c-erbb-2 HER2/neu encoded oncoprotein fragment p105 in normal pregnancies. In Vivo 11, Meden H, Mielke S, Wuttke W, Kuhn W (1997): Elevated serum levels of the c-erbb-2 encoded oncoprotein fragment in cases of pure preeclampsia and HELLP syndrome. J Obstet Gynaecol Res 23, Meden H, Mielke S, Marx D, Wuttke W, Kuhn W (1997): Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17, Meden H, Mielke S, Wuttke W, Kuhn W (1995): Increased serum level of c-erbb-2-coded protein p105 in patients with pre-eclampsia.[erhöhte Serumspiegel des c-erbb-2-codierten Proteins p105 bei Patientinnen mit Präeklampsie.] Gynäkol Geburtshilfliche Rundsch 35 (Suppl 1), Case Reports Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S (2009). Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. J Clin Microbiol, 2009 May 6. [Epub ahead of print] Mielke S, Potthoff K, Feuerhake F, Bley TA, Windfuhr M, Bertz H, Finke J (2007): Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation. Onkologie 30, Lohr J, Mielke S, Lübbert M, Behringer D (2003): Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In Vivo 17, Reviews Mielke S (2007): Individualized pharmacotherapy with paclitaxel. Curr Opin Oncol 19, Mielke S, Sparreboom A, Mross K (2006): Peripheral neuropathy, a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42, Mielke S, Solomon SR, Barrett AJ (2005): Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 7, Book Chapters and Contributions Mielke S (2009): Peripheral neuropathy. in: Encyclopaedia of Cancer. 2 nd edition 2008; hrsg. von Schwab M; Springer Verlag, Berlin, invited, in press

5 Mielke S, Barrett AJ (2009): Management of relapse and minimal residual disease after stem cell allotransplantation. in: Hematopoietic Stem Cell Transplantation in Clinical Practice. 1 st edition 2009; edited by Treleaven J & Barrett AJ; Elsevier Verlag, Edingburgh, Chapter 40: Finke J, Potthoff K, Mielke S, Bertz H (2002): Allogenic stem cell transplantation from related and unrelated donors for active leukemia or lymphoma: feasibility and results in elderly patients. in: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells Proceedings of the 5 th International Stem Cell Workshop, Bad Saarow/Berlin, Germany, April 26 th -28 th, st English- language edition 2002; hrsg. von Schultze W; Blackwell Verlag, Berlin, Wien, Meden H, Marx D, Raab T, Mielke S, Kron M, Wuttke W, Schauer A, Kuhn W (1994): Erhöhte Serumspiegel des Onkoproteins p185 (c-erbb-2) bei Patientinnen mit Ovarialkarzinom: Erste Ergebnisse mit einem neuen ELISA. Zitiert nach dem Buchbeitrag des Vortrags (gehalten von Meden am 7. Oktober 1994) in: 10. Arbeitsgespräch der Tumorimmunologie in der Gynäkologie, Ulm, 7. bis 8. Oktober 1994, Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie; hrsg. v. Kreienberg R., Grill HJ, Möbus V, Koldovsky U, Zuckschwerdt Verlag, München, Aktuel Onkol 86, 33-36